Literature DB >> 20040137

Case report: Oxymorphone-involved fatalities: a report of two cases.

Iain M McIntyre1, James L Sherrard, Craig L Nelson.   

Abstract

There has been an increased awareness of illicit opiate abusers using the narcotic oxymorphone (Opana) by inhalation. Many laboratory screening techniques currently in use cannot detect oxymorphone in blood or urine. Consequently, biological specimens containing low to moderate concentrations of oxymorphone will likely go undetected. The circumstances, pathology findings, and toxicology results of two fatalities involving oxymorphone are presented. An opiate confirmation gas chromatography-mass spectrometry (GC-MS) procedure, described in detail was able to detected, confirm, and quantify oxymorphone in both subjects. The blood concentrations were 0.05 mg/L (50 microg/L) and 0.12 mg/L (120 microg/L).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20040137     DOI: 10.1093/jat/33.9.615

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  3 in total

1.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

2.  Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Addict Biol       Date:  2014-07-31       Impact factor: 4.280

3.  Opana ER (Oxymorphone)-Induced Thrombotic Microangiopathy: An Atypical Presentation in a Patient With Hepatitis C.

Authors:  Hassan Mehmood; Muzammil Khan; Asghar Marwat; Medha Joshi; Varun Malhotra
Journal:  J Investig Med High Impact Case Rep       Date:  2018-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.